What We Are Trying to Accomplish
To invest in MS research by funding the:
- National Institutes of Health (NIH),
- Multiple Sclerosis Research Program (MSRP) at the Department of Defense, and
- National Neurological Conditions Surveillance (data collection) System.
Happening at the National Level
National Institutes of Health (NIH)
The NIH is the country’s premier medical research institution and the single largest source of biomedical research funding in the world. In FY2018, the NIH received a total of $37 billion to fund medical research. For FY2020, the National MS Society is advocating for a $2.5 billion increase in funding for the NIH, bringing its total funding to $41.6 billion.
MS Research Program (MSRP)
The MSRP is administered by the Department of Defense, and funded by Congress. The Multiple Sclerosis Research Program (MSRP) is a part of the larger Congressionally Directed Medical Research Programs, which fund focused and innovative research complementary to that of the NIH.
- Approximately 70,00 US veterans live with MS, and around 20,000 of those living with MS receive care through the Veterans Health Administration (VHA) each year. Around 12,000 seen by the VHA each year have been diagnosed with MS that was deemed "service-connected."
In FY2019, the MSRP received $6 million, bringing its total funding to date over $50 million. The Society asks Congress to provide $16 million for the MSRPP in FY2020.
National Neurological Conditions Surveillance System (NNCSS)
In 2016, the 21st Century Cures Act was signed into law, authorizing the Centers for Disease Control and Prevention to create a National Neurological Conditions Surveillance System to collect data on neurologic conditions to improve research and public health data on these conditions. The NNCSS is authorized for 5 years and received its first bath of funding in FY19. The Society has asked Congress to continue its $5 million investment in this important System in FY2020.
Position Papers & Other Support
Read these important documents to understand the issue.